PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC 50 s of 1.9 µM and 0.6 µM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways In Vitro PIP4K-IN-a131 (0-100 μM; 72 hours) is a potent antiproliferative agent with a clear selectivity toward cancer cells killing. PIP4K-IN-a131 eliminates cancer cells via a dual-inhibitory mechanism. PIP4K-IN-a131 causes inhibition of the PI3K/Akt/mTOR pathway only in normal BJ cells, but not in transformed counterparts. Inhibition of PIP4Ks by PIP4K-IN-a131 arrests normal cells at the G1/S phase of the cell cycle by suppressing the PI3K/Akt/mTOR signaling pathway via transcriptional upregulation of PIK3IP1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Normal and transformed BJ cells Concentration: 0-100 μM (MTT assay) Incubation Time: 72 hours Result: Selective killed cancer cells. RT-PCRCell Line: BJ cells Concentration: 5 µM Incubation Time: 24 hours Result: Induced the upregulation of PIK3IP1 mRNA levels. Form:Solid IC50& Target:IC50: 1.9 µM (PIP4K2A), 0.6 µM (PIP4Ks)